Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

hich may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2009, and statements regarding our clinical development programs, the effectiveness of our Vancocin and Cinryze sales efforts, our estimates of future tax rates, or our ability to execute a successful launch of Cinryze, our ability to conduct future studies with maribavir, and the timing and potential outcomes of the review of our regulatory submission related to an acute treatment indication for Cinryze.

Our 2009 revenue guidance is based upon our plans to remain vigorous in our opposition to any bioequivalence approach considered for use in approving generic formulations of Vancocin that does not require rigorous scientific methods to demonstrate safety and efficacy consistent with good medicine and science. There can be no assurance that the FDA will agree with the positions stated in our Vancocin related submissions or that our efforts to oppose the FDA's December 2008 bioequivalence guidance for Vancocin will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either our citizen petition for Vancocin or the approval of generic versions of Vancocin. If we are unable to change the recommendation set forth by the FDA in December 2008, the threat of generic competition will be high. The entry of competing generic products will significantly affect our sales of Vancoci
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 2014 The report “Smart Highway ... Management, Communication, Monitoring), and by Display (Variable Message ... segments the global market into various sub-segments with ... identifies the drivers and restraints for this market ... Browse 75 market tables and 37 figures spread ...
(Date:10/27/2014)... Pa. , Oct. 27, 2014 ... Foundation of America (CCFA) announced today the launch ... , an educational campaign designed to ... diseases (IBD) on the paired role of nutrition ... To view the multimedia assets associated with this ...
(Date:10/26/2014)... The report "Data Center Networking Market ... WAN Optimization Appliances]: Global Advancements, Worldwide Forecasts & ... networking market into various segments with an in-depth ... identifies the factors driving this market, various restraints ... the future roadmaps. , Browse 106 market data ...
(Date:10/25/2014)... 2014 The report “Adipic Acid ... Geography - Global Trends & Forecast to 2019” ... to market drivers, opportunities, and trends in different ... 27 figures spread through 217 slides and in-depth ... & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , Early ...
Breaking Biology Technology:Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4
... provided people with many items such as iPods, ... audio capabilities. Technology is evolving so quickly that ... years ago are now taken for granted. , ... understand how technology may evolve when entering into ...
... series of articles on raising capital from investors. This installment focuses ... time when raising equity capital, the offering terms are summarized in ... When dealing with angel investors , it is typical for ... angel investors will want to negotiate the initial term sheet, especially ...
... . - Oren Harari is coming to Milwaukee next ... of innovation. , ,Not just to manufacturers, who he will be ... to business organizations in a number of sectors, including technology. , ... to Compete in a Copycat Economy , he intends to deploy ...
Cached Biology Technology:Making deals with evolving technologies in mind 2Making deals with evolving technologies in mind 3Making deals with evolving technologies in mind 4Making deals with evolving technologies in mind 5Capital-raising term sheets for angels and venture capitalists 2Capital-raising term sheets for angels and venture capitalists 3Capital-raising term sheets for angels and venture capitalists 4Capital-raising term sheets for angels and venture capitalists 5Visions: Innovating like Madonna and Willie Nelson (and Steve Jobs) 2Visions: Innovating like Madonna and Willie Nelson (and Steve Jobs) 3
(Date:10/29/2014)... kind of stem cell, those referred to as ,facultative, ... is apparently nothing that differentiates these cells from the ... they retain the capacity to become stem cells again. ... an organ that hosts cells that stimulate tissue growth, ... case of a transplant. Knowledge of the underlying ...
(Date:10/29/2014)... Cancer Genomics of the Kidney consortium ( CAGEKID ... and exposure to aristolochic acid, an ingredient in ... Nature Communications , have important implications for public ... people every year, and in Central Europe incidence ... the International Cancer Genome Consortium (ICGC), has been ...
(Date:10/28/2014)... announced awards to expand the Office of Rare ... Advancing Translational Sciences (ORDR-NCATS) collaborative Rare Diseases Clinical ... scientists at 22 consortia will work with 98 ... investigate new treatments for patients with rare diseases. ... in fiscal 2014 funding from NIH. , Rett ...
Breaking Biology News(10 mins):A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2Kidney cancer in Central Europe 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3
... days over what they eat, and whether horse meat ... been dominating headlines globally - calling for new ... successful food identification and authentication. As companies and manufacturers ... the gullible public, it is estimated that up to ...
... 2013 Sanford-Burnham Medical Research Institute (Sanford-Burnham) and ... build a pipeline of therapeutic drugs aimed at ... needs. Under this agreement, Mayo Clinic scientists will ... for Chemical Genomics (Prebys Center) to conduct early-stage ...
... increasingly resembles lusher latitudes to the south, according to ... land surface and newly improved satellite data sets. ... the relationship between changes in surface temperature and vegetation ... Ocean. Results show temperature and vegetation growth at northern ...
Cached Biology News:DNA barcoding alone sufficient to detect fraudulent deer products 2DNA barcoding alone sufficient to detect fraudulent deer products 3Sanford-Burnham Medical Research Institute and Mayo Clinic extend collaborative agreement 2Amplified greenhouse effect shifts north's growing seasons 2Amplified greenhouse effect shifts north's growing seasons 3
Human HVEM/TNFRSF14 Allophycocyanin MAb (Clone 94801)...
LAL Chromogenic Endpoint assay...
RayBio Human Atherosclerosis Antibody Array 1.1 (4) with Accessory, detects 40 inflammatory factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Request Info...
Biology Products: